Placental Implications of Peroxisome Proliferator-Activated Receptors in Gestation and Parturition by Borel, Valerie et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2008, Article ID 758562, 9 pages
doi:10.1155/2008/758562
ReviewArticle
Placental Implications of Peroxisome Proliferator-Activated
Receptors in Gestation and Parturition
Valerie Borel,1,2 Denis Gallot,1,3 Geoffroy Marceau,1,2 Vincent Sapin,1,2 and Lo¨ ıc Blanchon1,2
1Universit´ e d’Auvergne, JE 2447, ARDEMO, 63000 Clermont-Ferrand, France
2INSERM, U.384, Laboratoire de Biochimie, Facult´ ed eM ´ edecine, 63000 Clermont-Ferrand, France
3CHU Clermont-Ferrand, Maternit´ e, Hˆ otel-Dieu, 63000 Clermont-Ferrand, France
Correspondence should be addressed to Vincent Sapin, vincent.sapin@u-clermont1.fr
Received 4 June 2007; Revised 13 August 2007; Accepted 26 October 2007
Recommended by Pascal Froment
The placenta is a transitory structure indispensable for the proper development of the embryo and fetus during mammalian
gestation. Like other members of the nuclear receptor family, the peroxisome proliferator-activated receptors (PPARs) are known
to be involved in the physiological and pathological events occurring during the placentation. This placental involvement has been
recently reviewed focusing on the early stages of placental development (implantation and invasion, etc.), mouse PPARs knockout
phenotypes,andcytotrophoblastphysiology.Inthisreview,wedescribetheplacentalinvolvementofPPARs(e.g.,fattransportand
metabolism, etc.) during the late stages of gestation and in the amniotic membranes, highlighting their roles in the inﬂammation
process (e.g., chorioamnionitis), metabolic disorders (e.g., diabetes), and parturition.
Copyright © 2008 Valerie Borel et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. THE PEROXISOME PROLIFERATOR-ACTIVATED
RECEPTORS (PPARs)
1.1. Nomenclatureandstructure
Discovered in 1990, PPARs are known for their biologi-
cal role in inducing the proliferation of peroxisomes in ro-
dents [1]. They are transcription factors belonging to the
ligand-activated nuclear hormone receptor superfamily [2]
andhavebeenidentiﬁedindiﬀerentspeciessuchasthexeno-
pus, mouse, rat, and humans. In all these species, PPARs
present three isotypes encoded by distinct single-copy genes:
PPARα (NR1C1), PPARβ/δ (also called NUC1 or NR1C2),
and PPARγ (NR1C3), located on chromosomes 15, 17, 6 in
the mouse and chromosomes 22, 6, 3 in humans, respec-
tively. The PPARγ gene alternative promoters give rise to
three diﬀerent isoforms named γ1, γ2, and γ3w h i c hd i ﬀer at
their 5 ends (seeFigure 1(a))[ 3].PPAR α, β,γ1/γ3, γ2tran s -
lation produces proteins of 468, 441, 475, and 505 amino
acids, respectively, with a molecular weight of 49 to 56kDa
[4]. By performing multiple PPAR nucleotide/protein align-
ments of PPARs in diﬀerent species, a strong interspecies
identity (human, mouse, rat, bovine, ≈90%) has been estab-
lished,illustratingastrongevolutionaryconservationamong
species by derivation from a common ancestor (Table 1).
PPARγ showsthehighestconservationintermsofcDNAand
proteins.
Like several other members of the nuclear receptor su-
perfamily, PPARs possess the typical structure organised in
six domains named A to F (see Figure 1(b))[ 5]. Domain
C (DBD: DNA binding domain) contains two zinc ﬁngers
and allows promoter target gene interaction and dimeriza-
tionwithitspreferentialnuclearreceptor:retinoidXreceptor
(RXR). The PPAR/RXR heterodimer binds to the target gene
promoter response element named peroxisome proliferator
response element (PPRE) which is made up of two half site
AGGTCA separated by one or two nucleotides (also called
DR1 or DR2 for direct repeat 1 or 2) and a 5  extension A
(A/T) CT. Domain E/F allows ligand binding and contains a
ligand-dependent transactivation function called AF2 (acti-
vating function 2). It is involved in dimerization and interac-
tion with cofactors.
1.2. PPARligands
As with the other nuclear receptors, the binding of the ligand
isakeystepinthecontrolofPPARtranscriptionalactivity.In2 PPAR Research
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Figure 1: (a) Schematic representation of PPARγ genes, mRNA, and proteins. The 5 exons A1, A2, B can be alternatively spliced to give rise
to the diﬀerent PPARγ isoforms. The boxes 1 to 6 correspond to exons which are common to PPARγ1, γ2, γ3 genes. ATG is the initiation
transcription site. The molecular weight of these isoforms ranges from 49 to 56kDa. (b) Schematic representation of typical nuclear receptor
structure. AF1: activating function 1 (ligand-independent function), AF2: activating function 2 (ligand-dependent function), NLS: nuclear
signal localization.
theabsenceofaligand,corepressorsandhistonedeacetylases
(HDAC) bind to PPARs and inhibit the transcription acti-
vation of target genes. PPAR ligands have the ability to dis-
sociate the corepressor complexes from the PPAR/RXR het-
erodimer,allowingthebindingofthecoactivatorsinorderto
initiate and activate transcription.
There are two kinds of ligands for the PPARs: natural
and synthetic. Among the natural ligands the monounsat-
urated fatty acids (FA) (e.g., oleic acid) and the polyunsat-
urated fatty acids (PUFA) (e.g., linoleic acid, linolenic acid,
and arachidonic acid) are described as ligands for PPARα,
PPARβ,a n dP P A R γ. They act with concentrations consis-
tent with those found in human serum [6]. The diﬀer-
ent PUFA metabolites: 8(S)- and 15-hydroxyeicosatetraenoic
acid(8(S)-and15-HETE),leukotrieneB4(LTB4),9-and13-
hydroxyoctadedienoic acid (9-HODE and 13-HODE) and
15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) are potent selec-
tive activators of PPARα and PPARγ. Some oxidized low-
density lipoproteins (LDLs), oxidized alkyphospholipids, ni-
trolinolenic acid, and prostaglandin metabolites can also ac-
tivate PPARγ [7]. Recently, it has been demonstrated that
P450 eicosanoids are potent PPARα and PPARγ ligands
[8]. Indeed, Ng et al. [8] have shown that P450 catalysed
arachidonicacidmetaboliteslike20-hydroxyeicosatetraenoic
acid (20-HETE) or 11, 12-epoxyeicosatrienoic acid (11, 12-
EET) can activate PPARα and PPARγ. These ligands in-
duce PPAR binding to PPRE and can modify the expres-
sion of PPARα responsive genes like apoA-I or apoA-IIValerie Borel et al. 3
in the same way than synthetic ligands. Thus the ﬁnely
regulated conversion of PUFAs to eicosanoids through ei-
ther the lipoxygenase, cyclooxygenase, or cytochrome P450
monooxygenase pathways may provide a mechanism for
the diﬀerential regulation of PPARα and PPARγ and their
respective target genes. PPARβ can be activated by diﬀer-
ent types of eicosanoids including prostaglandinA1 (PGA1)
and prostaglandin D2 (PGD2). Many synthetic ligands ex-
ist and have been used in PPAR work. These ligands in-
clude prostaglandin 12 analogs, pirinixic acid (Wy-14643)
for PPARα, hypolipidemic and hypoglycemic agents (non-
thiazolidinedione) for PPARβ, and thiazolidinediones (e.g.,
rosiglitasone, troglitazone) for PPARγ [2].
2. PPAR EXPRESSION PATTERNS
TheadultPPARexpressionpatternshavebeenextensivelyes-
tablished at the mRNA and protein levels in several species
(Table 2)[ 8, 9]. Several studies conducted during mam-
malian gestation have established the placenta as an im-
portant expression site of the diﬀerent PPARs isoforms.
Our review will focus only on term placental expression
and on the amniotic/fetal membranes. The placental dy-
namic expression of the 3 PPARs during early and midges-
tation (of mouse, rat, and human) is well described in
Fournier et al., 2007 [4]. In rat placenta, all three PPAR
isoforms are ubiquitously expressed from 11 days post-
coitum (dpc) [10]. Both PPARβ/δ and PPARγ are ex-
pressed after 8.5dpc in mouse placenta. By immunohis-
tochemistry and RT-PCR, the three PPAR isoforms are
been shown to be expressed in the villous trophoblastic
cells and syncytiotrophoblasts of the human term placenta
[4]. To extend the previously published results [11]a n d
to assess the potential importance of PPAR proteins in fe-
tal membranes, RT-PCR and immunohistochemistry ex-
periments were performed on human term placental sam-
ples. The three PPARs are present in total placenta, am-
nion, chorion, and in amnion-derived WISH epithelial cell
line at the mRNA (see Figure 2(a)) and protein levels (see
Figure 2(b)). The expression of PPARα and PPARγ seems
to be weaker than that observed for PPARβ/δ. In addi-
tion, a greater ampliﬁcation of the PPARγ cDNA is obtained
in chorion than in amnion, where PPARγ is almost unde-
tectable.
3. IMPLICATIONS OF PPARs IN PLACENTA AND
FETAL MEMBRANES
3.1. PlacentalandamnioticpresenceofPPARsligands
The lipids of human amnion and chorion are enriched in
the essential fatty acid arachidonic acid, which is the pre-
cursor of all the prostaglandins of the 2 series [13]. Sixty-
six percent of the arachidonic acid of the human fetal mem-
branes are available in the glycerophospholipids of these tis-
sues and can easily be converted into PGD2 [14]. The pla-
centa produces considerable amounts of PGD2 [15]. The
enzymes necessary to convert PGD2 into prostaglandin J2
(PGJ2) are present and coexpressed with PPARγ in placenta.
15-Deoxy-Δ12,14-PGJ2 (15dPGJ2) and its precursor PGD2
are present in amniotic ﬂuid at concentrations that do not
exceed 3nM [16]. However, this amniotic ﬂuid concentra-
tion cannot be an exact representation of the physiological
placental reality for PPARs ligands because the nuclear con-
centration is not measured. The maternal blood may also
be a source of PPAR ligands for the human placenta and
the fetal membranes. It has been established that a heat-
stable compound (not a protein, but rather a prostanoid
or a fatty acid) is detected in maternal blood serum and
is able to activate the PPARγ [17]. The presence of classi-
cal and new PPARs ligands (e.g., P450 eicosanoids, PUFA
metabolites) in placenta and fetal membranes suggests that
they could activate PPAR, induce PPAR binding to PPRE,
and modify the expression of PPAR target genes; but this hy-
pothesis has to be conﬁrmed by further analysis, based on
PPARs activation in other organs. For example, PUFAs, such
as and eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), increased PPARγ mRNA expression and bind-
ing to PPRE in renal tubular epithelial cell line (HK-2). Fur-
thermore, they downregulate LPS-induced activation of NF-
κBv i aaP P A R γ-dependent pathway in HK-2 cells [18]. An-
other example showed that PGD2 is among the most abun-
dantly produced prostaglandins in synovial ﬂuid by syn-
ovial ﬁbroblasts [19]. It can be converted into PGJ2. It has
been demonstrated that PPARγ ligands (15dPGJ2) inhibit
IL-1β–induced production of nitric oxide (NO) and matrix
metalloproteinase-13 (MMP-13) in chondrocytes. This inhi-
bition was PPARγ-dependent and occurred at the transcrip-
tional level, through repression of NF-κB signalling [20].
These two examples support a role of PPAR ligands in fetal
membranes.
3.2. FundamentalimplicationsofPPARsduring
earlyplacentation
As a determining result, the knockout of the PPARγ in
mice [21] yielded the ﬁrst ﬁndings indicating the impor-
tance of this factor in early embryonic and perinatal de-
velopment. These results are concomitant with those ob-
tained by the generation of RXRα or β null mice (PPARγ
partner in the functional heterodimer), also showing an
embryonic lethality explained by the lack of generation of
a functional labyrinthine zone [22]. Furthermore, comple-
mentary studies conducted by the inactivation of PPARγ
coactivatorsorcoregulators,suchasperoxisomeproliferators
activator receptor-binding protein (PBP) and peroxisome
proliferator-activated receptor-interacting protein (PRIP),
also lead to severe placental dysfunction, such as inadequate
vascularisation of the structure [23–25]. Recently, Barak et
al. also demonstrated that the inactivation of PPARβ/δ led
to the formation of abnormal gaps and a thinner but fully
diﬀerentiated vascular structure in the placentodecidual in-
terface [26]. These results establish the nonredundant roles
of PPARγ and PPARβ/δ in early mouse placental develop-
ment. By contrast, the inactivation of PPARα has no eﬀect
on placental formation or on the developing foetus and by
the way theirs possible roles during pregnancy had to be
clariﬁed [2]. In humans, the studies are almost exclusively4 PPAR Research
Table 1: Percentage of nucleotide and amino acid identity between the human, mouse, rat, and bovine PPAR sequences. No PPARγ3
alignment was carried out owing to lack of data on diﬀerent species. The diﬀerent sequences came from Ensembl and were aligned with
Genomatix software.
cDNA homology (%) Protein homology (%)
Mouse Rat Bovine Mouse Rat Bovine
Human relative
identity percent
PPARα 44 64 72 92 92 94
PPARβ 60 69 75 92 91 95
PPARγ1 7 98 4 7 8 9 89 7 9 7
PPARγ2 8 68 6 8 8 9 69 5 9 5
Table 2: Summary of PPAR expression patterns.
(a) Global expression pattern
Gene Species Expression localization References
PPARα
Rodents Cardiomyocytes [6, 8]
Hepatocytes
Human
Heart
[6, 8] Kidney
Large intestine
Leydig and seminiferous tubule cells [12]
Liver [6, 8]
Skeletal muscle
Uterus
[12] Ovary (Theca and stroma cells)
PPARβ Rodents Ubiquitous [6, 8]
Human Ubiquitous [6, 8]
PPARγ
Rodents
Brown and white adipose tissue
[6, 8] Lymphoid organs
Retina
Skeletal muscle
Uterus
[12] Granulosa cells, corpus luteum
Human
Colon
[6, 8]
Kidney
Liver
Skeltal muscle
Vascular endothelium
White adipose tissue
Sertoli cells
[12] Uterus
Granulosa cells
(B) Placental expression pattern
PPARα, β, γ
Rodents Term placenta [4, 9]
Human Villous trophoblastic cells and syncytiotrophoblasts [4, 9, 10]
Amnion, chorion, and amnion derived-WISH cell line
focused on the PPARγ roles during early placentation. It has
been clearly established that all three PPARs can stimulate or
inhibit the diﬀerentiation and/or proliferation of the villous
cytotrophoblasts into syncytiotrophoblasts and the synthesis
of chorionic gonadotrophic hormone, and may hamper ex-
travillous trophoblastic cell invasion (for more details, see
Fournier et al., 2007 [4]).
3.3. RolesofPPARsintheuptakeandtransportof
trophoblasticlipids
As one of the ﬁrst functions described for PPARγ in other
tissues, trophoblastic lipid uptake and accumulation are also
regulatedin part by this factor[27]. ThePPARγ ligands seem
to increase the uptake and accumulation of the fatty acids inValerie Borel et al. 5
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Figure 2: PPARs expression in term placenta and amniotic membrances. (a) RT-PCR assays of PPARα,P P A R β,a n dP P A R γ mRNA in
amnion, chorion, placenta, and WISH cells. PCR products were analyzed on 1.8% agarose gel and stained with ethidium bromide. 36B4
corresponds to the housekeeping gene. A: Amnion, C: Chorion, A+C: Amnino+Chorion, P: Total placenta, W: WISH cells. (b) PPARs
immunostaining of amnion and chorion. Note that all PPARs are expressed in nucleus. Magniﬁcation: x200.
human placenta [28]. This regulation is associated with an
enhanced expression of adipophilin (fat droplet-associated
protein)andfattyacidtransportproteins(1and4)inhuman
trophoblasts [28–30]. These results were conﬁrmed recently
bytheinvivoactivationofPPARγ byitsagonistrosiglitazone
in mice, which also leads to the enhancement of the previ-
ous described genes plus two new ones involved in the lipid
transport: S3-12 (plasma associated protein) and myocardial
lipid droplet protein/MLDP [27]. Taken together, these re-
sults conﬁrm the results obtained on PPARγ-null mutants:
the absence of the lipid droplets normally present around the
fetal vessels in the wild-type placenta [21].
3.4. PPARsinplacentalinﬂammatoryresponseandin
theparturitionsignalling
At this stage of our knowledge of PPARs, the most inter-
esting results have been obtained with the study of their
involvement in the inﬂammation process, which may be
linked to labor at term and also to the premature rupture
of fetal membranes (see Figure 3). Term labor is associ-
ated with an increase in proinﬂammatory proteins and cy-
tokines such as IL1β, IL6, IL8, IL10, and TNF-α. This in-
crease in proinﬂammatory proteins and cytokines induces
uterinecontractions.PPARγ ligandshavebeendemonstrated
to inhibit the secretion of IL6, IL8, and TNF-α in amnion
and chorion [31], highlighting the role of PPARs in the reg-
ulation of the inﬂammatory response in human gestational
tissues and cells [32–35]. The parathyroid hormone-related
protein (presenting a cytokine-like action) is involved in
many processes during normal and pathological pregnan-
cies, and is decreased by PPARγ stimulation [36], which also
blocks proinﬂammatory cytokine release by adiponectin and
leptin [37]. The production of prostaglandins by the en-
dometrium, the myometrium, and the fetal membranes in-
duces the contraction of the myometrium during labor. This
generation of uterotonic prostaglandins correlates with the
increased prostaglandin-endoperoxide synthase type 2/cy-
clooxygenase type 2 (COX-2) activity and the increased se-
cretory phospholipase A2-IIA (sPLA2) mRNA, proteins and
activities. By inhibiting the production of the COX-2 and
sPLA2 in fetal membranes, PPARγ promotes the quiescence
of the uterus during gestation [34]. The molecular action
of 15dPGJ2 seems to involve interactions of the NF-Kappa
B signaling pathway, inducing reduction of PGF2α,P G E 2 ,
and MMP9 release in the placental environment [31]. This
suppressive action of PPARγ on inﬂammation is apparently
time-dependent during pregnancy. The PPARγ level of ex-
pression remains stable throughout gestation, except for the
period just before labor, when its expression in fetal mem-
branes declines. This reduction is coincidental with a rel-
ative increase in COX-2 expression [38]. Further work has
shown this simple scheme to be more complex. While the
expression of PPARα does not change at term in amnion,
it decreases in chorion. An increase was also demonstrated
for PPARβ/δ in chorionic and amniotic zones [11]. These
last two ﬁndings raise the question of the involvement of
the α and β isoforms in this process. The absence of a
real link between COX-2 and PPARγ is presented by Lind-
strom and Bennett [39]. Finally, the PPAR action seems to
be concentration-dependent. A small amount of 15dPGJ2
(<0.1μM) acts through the PPARγ signaling pathway, where
at high concentration (1μM) its actions are most proba-
bly mediated through other pathways: PPARβ/δ and/or an6 PPAR Research
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Figure 3: Schematic representation of PPARγ implication in pregnancy maintenance and labor. IL1β: Interleukin 1β; IL6: Interleukin 6;
IL8: Interleukin 8; IL10: Interleukin 10, TNFα: Tumor Necrosis Factor α; COX2: Cyclo-oxygenase type 2; PLA2: Phospholipase A2; NF-κB:
Nuclear Factor-Kappa B; MMP9: Matrix Metalloproteinase 9; 15dPGJ2: 15-Deoxy-Δ12, 14-prostaglandin J2.
inhibition of NF-κB independent of PPARs [35]. Further-
more, 15dPGJ2 and troglitazone were also demonstrated to
have some antiinﬂammatory or apoptosis-induction speciﬁc
eﬀects by PPARγ-independent pathways. This was suggested
by the work of Lappas et al. on human gestational tissues,
demonstrating that this eﬀect could passed by antagonist ef-
fect of 15dPGJ2 on the NF-κB pathways and antioxidant ef-
fects of the troglitazone, a synthetic ligand of PPARγ [31].
3.5. PPARsinplacentalandamniotic
membranespathologies
In contrast to the diﬀerent roles described for PPARs dur-
ing human placentation, only a few studies on PPARs and
placental pathologies have been conducted. In choriocarci-
nomaandhydatiformmoles,adownregulationofthePPARγ
expression is observed but this real inﬂuence needs to be
elucidated [40]. The potential involvement of PPARγ on
preeclampsiaissuggestedbythefactthatthispathologyisas-
sociated with an increased peroxidation in trophoblasts [41,
42]. An overproduction of 15-HETE has also been noted,
suggesting a deregulation of PPARγ [43]. This can cause a
strong transactivation of PPARγ during early pregnancy, re-
sulting in a reduction of extravillous trophoblastic invasion,
one cellular explanation often cited in the physiopathology
of preeclampsia [44, 45]. Other abnormal transactivation of
PPARsmaybe hypothesized to explainplacentalpathologies.
The 15dPGJ2 has been shown to induce apoptosis of the pla-
cental (JEG-3) and amniotic (WISH) established cell line,
[46, 47]. An excess of 15dPGJ2 production can be a source of
placental dysfunction linked to an increase in trophoblastic
death. It is also established that deletion of PPARγ,P P A R β/δ,
and some of their coactivators (PBP, PRIP, and RAP250) in-
duce abnormal placental phenotypes (abruption, reduction
of fetomaternal exchanges, and alterations of trophoblastic
diﬀerentiation)innullmutants[21,23,24,26,48,49].Chro-
mosomal and/or genetic alterations (point mutation or dele-
tion) may occur for these genes, inducing human placental
alterations.Theplacental11β hydroxysteroiddehydrogenase
type 2 is a target gene of PPARs [50]. This enzyme plays a
key role in fetal development by controlling fetal exposure to
maternal glucocorticoids. An abnormal regulation by PPARs
mayresultinanabsenceoffetalprotection.Intheratplacen-
tal HRP-1 established cell line, the phthalate and derivatives
transactivate PPARs (α and γ) induced an increase in uptake
rates of fetal essential fatty acid and the transport of arachi-
donic and docosahexaenoic acid [51]. If such a mechanism
canbeinducedbythephthalatesduringhumanplacentation,
this may strongly aﬀect the fetal essential fatty acid content
during growth.
Gestational diabetes is linked to impaired lipids metabo-
lism [52]. Decreased 15dPGJ2 in blood of diabetic mothers
is also linked to a decrease in placental PPARγ expression.
The inhibition of PPARγ results in an induction of a pla-
cental proinﬂammatory environment associated with an in-
crease in nitrogen monoxide production and release, which
can impair fetoplacental development [53, 54].
The PPAR regulation of inﬂammation may be very im-
portant in another obstetrical pathology of the amniotic
membranes: the chorioamnionitis. This pathology, usually
due to an ascendant colonization of pathogenic microor-
ganisms from the vagina to the uterus, is closely associated
with preterm labor and premature rupture of membranes
(chorion and amnion). These ruptures of membranes seem
to arise from deregulated proinﬂammatory factor synthesis.
It has already been reported in this pathology that IL1β,I L 6 ,Valerie Borel et al. 7
IL8, TNF-α, and prostaglandinE(2) show inadequate con-
centrations in placental membrane and in amniotic ﬂuid
[55–58]. As PPARs may be involved in the occurrence and
control of this inﬂammatory response, further studies are
needed to assess their importance in this process and to ﬁnd
new possible therapeutic strategies to prevent this damaging
pathology.
More generally, the use of natural and synthetic PPAR
ligands looks to be a promising way in preventing placental
pathologies such as endometriosis or preeclampsia. An in-
teresting study also demonstrates that the reduction of LPS
induction of cytokines is reduced by PPARγ ligands in fetal
membranes. Nevertheless, the few studies already conducted
were done practically only on animal (rodent) models and
looks to have positive eﬀects on the pathologies (for review
see Toth et al. [59]). Till now, the major problem using, for
example, TZD (thiazolidinedionzes) linking to the PPARγ
pathways still the numerous adverse eﬀects of this kind of
treatment (e.g., weight gain, anemia, leukopenia, etc.). These
facts and the potential placental impacts raised also the ques-
tion of the use of these medical drugs to treat the gestational
diabetes. Perhaps, at the level of clinician actual knowledge,
PPARγ and its ligands could be used in a ﬁrst time, only as
good early marker candidates for the diagnosis of pregnancy
pathologies like, for example, preeclampsia.
4. CONCLUSION
SincethediscoveryofthePPARs,therehasbeenamarkedin-
crease in available data on their involvement in mammalian
development. Concerning the placenta, all PPARs, but par-
ticularlyPPARγ,areessentialformultiplephysiologicalfunc-
tions of the trophoblastic and amniotic parts, leading to ma-
jor involvement of PPARs in the pathophysiology of gesta-
tional diseases. However, special care must be taken when
this particular PPAR signaling cascade is involved, because
part of the regulation may involve PPAR ligand signalling
(by the natural 15dPGJ2 ligand or the troglitazone synthetic
ligand) but may be transduced by independent nuclear re-
ceptor pathways (as, e.g., by antagonizing eﬀects on NF-κB
pathway for 15dPGJ2 and by acting as an antioxidant for
troglitazone). This last point introduces a new level of com-
plexity in PPAR biology. It does not close preclusion of the
eventualuseofPPARsfortherapeutictreatmentduringpreg-
nancy, but future medical applications seem still to be a long
way oﬀ. We can reasonably expect to see some obstetrical use
of PPARs in diagnosis (detection of PPARs mutations in in-
trauterine growth retardation, predisposition of preeclamp-
sia) and therapeutics (tocolysis or treatment of chorioamni-
otis).
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